MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease

M Eslam, AJ Sanyal, J George, A Sanyal… - Gastroenterology, 2020 - Elsevier
Fatty liver associated with metabolic dysfunction is common, affects a quarter of the
population, and has no approved drug therapy. Although pharmacotherapies are in …

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

Z Younossi, QM Anstee, M Marietti, T Hardy… - Nature reviews …, 2018 - nature.com
NAFLD is one of the most important causes of liver disease worldwide and will probably
emerge as the leading cause of end-stage liver disease in the coming decades, with the …

Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis

AM Diehl, C Day - New England Journal of Medicine, 2017 - Mass Medical Soc
Nonalcoholic steatohepatitis is a major cause of cirrhosis and liver cancer. It is associated
with visceral adiposity and the metabolic syndrome and is nearly as common as type 2 …

Genetics and epigenetics of NAFLD and NASH: Clinical impact

M Eslam, L Valenti, S Romeo - Journal of hepatology, 2018 - Elsevier
Non-alcoholic fatty liver disease (NAFLD) is now recognised as the most common liver
disease worldwide. It encompasses a broad spectrum of conditions, from simple steatosis …

Hepatic stellate cells as key target in liver fibrosis

T Higashi, SL Friedman, Y Hoshida - Advanced drug delivery reviews, 2017 - Elsevier
Progressive liver fibrosis, induced by chronic viral and metabolic disorders, leads to more
than one million deaths annually via development of cirrhosis, although no antifibrotic …

Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications

R Weiskirchen, S Weiskirchen, F Tacke - Molecular aspects of medicine, 2019 - Elsevier
Fibrosis denotes excessive scarring, which exceeds the normal wound healing response to
injury in many tissues. Although the extracellular matrix deposition appears unstructured …

Noninvasive biomarkers in NAFLD and NASH—current progress and future promise

VWS Wong, LA Adams, V de Lédinghen… - Nature reviews …, 2018 - nature.com
Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is
the most common chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH) is …

Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases

LA Adams, QM Anstee, H Tilg, G Targher - Gut, 2017 - gut.bmj.com
Key physiological functions of the liver, including glucose and lipid metabolism, become
disturbed in the setting of non-alcoholic fatty liver disease (NAFLD) and may be associated …

Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers

E Vilar-Gomez, N Chalasani - Journal of hepatology, 2018 - Elsevier
The correct identification of patients at increased risk of non-alcoholic steatohepatitis
(NASH) and advanced fibrosis is a critical step in the assessment of non-alcoholic fatty liver …

Lean NAFLD: a distinct entity shaped by differential metabolic adaptation

F Chen, S Esmaili, GB Rogers, E Bugianesi, S Petta… - Hepatology, 2020 - journals.lww.com
Conclusions This study demonstrates that E. multilocularis can induce T‐cell exhaustion
through inhibitory receptor TIGIT, and that blocking this checkpoint may reverse the …